How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer by Prazeres, Hugo et al.
SAGE-Hindawi Access to Research
Journal of Thyroid Research
Volume 2011, Article ID 678357, 10 pages
doi:10.4061/2011/678357
Review Article
How to Treat a Signal? Current Basis for
RET-Genotype-OrientedChoice of Kinase Inhibitors for
the Treatment of Medullary Thyroid Cancer
Hugo Prazeres,1,2,3 Joana Torres,1 FernandoRodrigues,4 Joana P. Couto,1,3
Jo˜ ao Vinagre,1,3,5 ManuelSobrinho-Sim˜ oes,1,3,6 andPaulaSoares1,3
1Cancer Biology Group, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP),
Rua Dr. Roberto Frias, s/n, 4200-465 Porto, Portugal
2Molecular Pathology Service, Portuguese Institute of Oncology of Coimbra FG, EPE, Avenida Bissaya Barreto, 98,
3000-075 Coimbra, Portugal
3Department of Pathology, Faculty of Medicine of Porto University, Al. Prof. Hernˆ ani Monteiro, 4200-319 Porto, Portugal
4Endocrinology Service, Portuguese Institute of Oncology of Coimbra FG, EPE, Avenida Bissaya Barreto, 98,
3000-075 Coimbra, Portugal
5Abel Salazar Biomedical Sciences Institute (ICBAS), Lg. Prof. Abel Salazar, 4099-003 Porto, Portugal
6Department of Pathology, Hospital S˜ ao Jo˜ ao, Al. Prof. Hernˆ ani Monteiro, 4200-319 Porto, Portugal
Correspondence should be addressed to Paula Soares, psoares@ipatimup.pt
Received 11 February 2011; Accepted 10 April 2011
Academic Editor: Maria Jo˜ ao M. Bugalho
Copyright © 2011 Hugo Prazeres et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The signiﬁcance of RET in thyroid cancer comes from solid evidence that, when inherited, an RET activating mutation
primes C-cells to transform into medullary carcinomas. Moreover, environmental exposure to radiation also induces rearranged
transforming RET “isoforms” that are found in papillary thyroid cancer. The RET gene codes for a tyrosine kinase receptor that
targets a diverse set of intracellular signaling pathways. The nature of RET point mutations predicts diﬀerences in the mechanisms
by which the receptor becomes activated and correlates with diﬀerent forms of clinical presentation, age of onset, and biological
aggressiveness. A number of RET-targeting Tyrosine Kinase Inhibitors (TKIs) are currently undergoing clinical trials to evaluate
their eﬀectiveness in the treatment of thyroid cancer, and it is conceivable that the RET genotype may also inﬂuence response to
these compounds. The question that now emerges is whether, in the future, the rational for treatment of refractory thyroid cancer
will be based on the management of an abnormal RET signal. In this paper we address the RET-targeting TKIs and review studies
about the signaling properties of distinct RET mutants as a means to predict response and design combinatorial therapies for the
soon to be available TKIs.
1. The RET TyrosineKinase Receptor
TargetsaDiverseSpectrumof
IntracellularSignalingPathways
RET (Rearranged during Transfection) encodes a mem-
brane receptor tyrosine kinase (RTK) composed of four
extracellular cadherin-like motifs and a cysteine-rich region,
a transmembrane portion, and an intracellular domain
with tyrosine kinase activity [1]. The RET signaling path-
ways are outlined in (Figure 1). RET signals through
a ligand/coreceptor/RET multiprotein complex instead of
the usual receptor/ligand binding. To date, several ligands
of the glial-derived neurotrophic factor (GDNF) family,
which include GDNF, artemin, neurturin, and persephin
and a family of GPI-linked RET coreceptors (GFR1-4), have
been identiﬁed [2]. The formation of ligand/coreceptor and
RET complexes results in RET dimerization and triggers
autophosphorylation atintracellulartyrosine residues. Phos-
phorylated tyrosine 687 (Y687), serine 696 (S696), Y752,
Y791, Y806, Y809, Y826, Y864, Y900, Y905, Y928, Y952,
Y981, Y1015, Y1029, Y1062, Y1090, and Y1096 constitute
docking sites for numerous intracellular adaptor proteins2 Journal of Thyroid Research
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Figure 1: Outline of RET signalling pathways.
such as RAC1-guanine exchange factor (GEF) [3], growth
factor receptor-bound (GRB) docking proteins GRB7/10
[4], chicken Rous sarcoma virus oncogene (c-Src), focal
adhesion kinase (FAK) [5], phospholipase C-γ (PLC-γ)a n d
Src homologue collagen (Shc), insulin receptor substrate 1/2
(IRS1/2), ﬁbroblast growth factor substrate 2 (FRS2), or
downstream of kinase 1/4/5 (DOK1/4/5) (reviewed by De
G r o o te ta l .[ 6]).
Phosphorylation of intracellular target proteins
activates several downstream pathways which include
mitogen-activated protein kinase cascade: rat sarcoma
oncogene/rapidly accelerated ﬁbrosarcoma/extracellular
regulated kinase 1/2 (RAS/RAF/ERK1/2), the phosphatidyli-
nositol 3-kinase/protein kinase B pathway (PI3K/AKT)
[7, 8], the c-Jun N-terminal kinase pathway (JNK) [9],
p38, enigma extracellular regulated kinase 5 (ERK5), the
cAMP-responsive element-binding protein, and the signal
transducer and activator of transcription 3 (STAT3) (for a
review see Arighi et al. [10]a n dD eG r o o te ta l . [6]. More
recently, Gujral et al. [11] have shown that RET mediates
direct tyrosine phosphorylation of beta-catenin, which
associated with an induction of the WNT pathway, that
accounts for a part of RET tumorigenic ability in vivo [11].
Many of the above-mentioned intracellular signalling
pathways are otherwise known to be general signal transduc-
ing pathways targeted not only by RET, but by other RTKs
as well. Yet, RET is the main RTK targeted for genetic lesions
in thyroid cancer. The transforming ability of activated RET,Journal of Thyroid Research 3
whichwasactuallyonthebasisofitsisolationasanoncogene
[12], could be attributable to the diversity of its signalling
which covers several hallmarks of cancer [13].
Increased growth signals and proliferation result from
the activation of the RAS/RAF/ERK1/2 cascade and phos-
phorylation of STAT3 [14, 15].
Cell migration is dependent on RET-mediated activation
ofRAC1andJNK[3,16],andFAK[5]isalsoreportedtoplay
a role in cell migration and to be required for invasion and
metastatic behaviour [5, 17].
Inﬂammation (regarded as the 7th hallmark of cancer
[18]) has also been shown to operate as a major compo-
nent downstream of oncogenic RET mutations. In freshly
isolated human thyrocytes, the activation of RET generates
a transcriptional program that is similar to that which occurs
duringinﬂammation[19]inducingtheexpressionofvarious
inﬂammatory factors [19–21]. Furthermore, key protein
components of the RET-activated “inﬂammatory” program
were found in tumor specimens taken by biopsy, and larger
amounts of these inﬂammatory molecules were found in the
primarytumorsofpatientswithlymph-nodemetastasisthan
in primary tumors in the absence of lymph-node metastasis
(reviewed in [22]). These and other results ([23, 24]; [25])
connect the activation of RET to inﬂammation.
2.HereditaryMTC-AssociatedActivating
MutationsClusterat SpeciﬁcFunctional
Domainsof theRETReceptor Kinase
Overall, as stated before, varied signalling properties, cover-
ing multiple hallmarks of cancer, might aﬀord explanation
for the ability of RET to transform certain cell types.
Nonetheless, the most solid grounds for the signiﬁcance
of RET as a cancer gene come from the fact that, when
inherited, an RET germline point mutation alone primes
a speciﬁc spectrum of tissues to develop endocrine tumors
[26, 27]. Carriers of RET germline mutations develop
hereditary medullary thyroid carcinoma (hMTC) as the
ﬁrst and most common clinical presentation. Along with
hMTC, patients present with pheochromocytoma (tumor
of the adrenal medulla) and parathyroid adenomas. This
syndromic condition is referred to as Multiple Endocrine
Neoplasia type 2 (MEN2) [28]. Penetrance for hMTC is near
complete, which highlights the critical role of RET activation
in the development of MTC and can be further taken to
pinpoint RET as a relevant therapeutic target for MTC.
In hMTC, RET mutations occur in a speciﬁc spectrum
of codons and result in gain of function, increased
kinase activity, and receptor activation [29]. Mutational
hotspots are located at the cysteine-rich region of the
extracellular domain and in the intracellular tyrosine kinase
domain [28]. The clustering of mutations in hotspots
might be explained by the fact that proto-oncogene
a c t i v a t i o nr e q u i r e sc h a n g e sa tr e s i d u e st h a ts p e c i ﬁ c a l l y
interact in speciﬁc ways with receptor function, and
thus mutations cannot occur in a widespread manner. A
comprehensive description of all known germline RET
variations can be found at the MEN2 RET database
(http://www.arup.utah.edu/database/MEN2/MEN2Welcome).
The most common RET germline mutations are missense
substitutions of extracellular cysteine residues, occurring at
cysteine codon 634 in 80% of cases. Cysteine codons 609,
611, 618, 620, and 630 are less frequently aﬀected. Other
noncysteineextracellulardomainmutations,locatedatexons
5 and 8, have been detected [30]. Tyrosine kinase domain
mutations aﬀect a more varied spectrum of amino acids,
and most frequently recurring mutations replace Met918,
Val804,Leu790,Tyr791,andAla883.Lessfrequently,residues
768, 876, 891, 886, and 912 are aﬀected. Rare mutations
found in isolated families have been reported, comprising
homozygous mutations [31], duplications [32], and double
mutations [33].
Besides the point mutations found in MTC, an alter-
native somatic genetic event that causes RET activation is
found in the papillary type of thyroid carcinoma (PTC).
This involves chromosomal translocations between RET and
a number of other loci, referred in general as RET/PTC
rearrangements, which interestingly occur as alternative
events to the V600E somatic BRAF mutation [34].
3.DistinctRETMutationsDetermine
Different Clinical Presentationsof
MEN2 andPredictAge of Onset of hMTC
In MEN2 there are consistent genotype/phenotype corre-
lations that underlie aspects such as clinical manifestation,
RET activation mechanisms, and disease penetrance, allow-
ing for a mutation-speciﬁc classiﬁcation of MEN2 [28]. In
clinical terms, three disease phenotypes can be recognized:
MEN2A, MEN2B, and a familial form of medullary thyroid
carcinoma (FMTC). MEN2A was found to be associated
with substitutions at one of six speciﬁc cysteine residues
in exons 10 (609, 611, 618, 620) and 11 (630 and 634).
M E N 2 Ac y s t e i n em u t a t i o n sg i v er i s et oM T Ca ty o u n ga g e
(onset at 5 to 25 years), along with variable expression of
pheochromocytoma (50%) and hyperparathyroidism (15–
30%) [28]. MEN2B, on the other hand, is mainly caused by a
speciﬁcmissensemutationlocatedattheRETtyrosinekinase
domain (Met918Thr), which accounts for 95% of cases [35].
A second tyrosine kinase domain substitution (Ala883Phe)
has been detected in a small proportion of MEN2B patients
[36]. Additionally, double mutations aﬀecting codons 804
and 805 and 804 and 806 were described in individual
MEN2B cases [33, 37]. MEN2B kinase domain mutations
give rise to a more complex clinical phenotype characterized
byanearlyonset(sometimes<1yearold)andveryaggressive
formofMTC,concomitantwithpheochromocytomain50%
of cases and accompanied by other nonneoplastic features,
such as mucosal neuromas of the tongue, lips, and eyelids,
ganglioneuromatosis of the gastrointestinal tract, thickening
of corneal nerves, and Marfanoid habitus [38]. In FMTC
the only disease manifestation is MTC, which usually occurs
in adult age, with no additional endocrinopathies. RET
mutations with low clinical expression, involving codons
321, 533, 768, 790, 791, 804, and 891, may be found in these4 Journal of Thyroid Research
families [28]. Occasionally, patients with these mutations
may also develop the MEN2A phenotype, showing that
FMTC and MEN2A represent a continuum of clinical
expression in a common genetically related disorder [39–
42]. Age-dependent penetrance for MTC in MEN2 is also
codon speciﬁc, and classiﬁcation of the risk of developing
MTC can be done based on the genotype (reviewed by Raue
and Frank-Raue in [43]). This is of clinical relevance because
the ideal timing of prophylactic thyroidectomy should take
into consideration the balance between the adverse eﬀects
of thyroidectomy at early ages and the individual risk
of developing MTC. Comprehensive guidelines have been
issued by the American Thyroid Association concerning
this aspect [44]. In general, RET mutations with a very
high risk of producing MTC (risk level D), comprising all
the MEN2B mutations, require surgery before 1 year of
age. RET mutations at codon Cys634 constitute risk level
C and are managed by thyroidectomy before 5 years old.
Level B mutations encompass the changes in the remaining
extracellular cysteine codons 609, 611, 618, 620, and 630. In
these cases, surgery is advised before 5 years old; however
it can be postponed until calcitonin level rise. Risk level A
accounts for the FMTC mutations, for which surgery before
5 yearsold is not required and can be delayed until calcitonin
levels rise.
4. The Natureof SomaticRET Mutations
Inﬂuences the Prognosis of Sporadic MTC
Aside from germline mutations, a somewhat similar spec-
trum of somatic mutations is observed in about 50 to
60% of the cases with sporadic MTC. A catalogue of
somatic mutations can be found at the COSMIC database
(http://www.sanger.ac.uk/genetics/CGP/cosmic/). The most
frequentsomaticlesionistheprototypicMEN2BMet918Thr
mutation at exon 16, which comprises up to 60% of the
mutation positive cases. Moreover, patients in which tumors
harbor MEN2B mutations have a higher prevalence and
number of lymph node metastases, present more often with
multifocal tumors and with persistent disease at advanced
stage, indicating that among the sporadic MTCs, cases with
somatic MEN2B mutations are associated with the worst
prognosis[45,46].Interestingly,caseswithRETmutationsat
the cysteine cluster have the most indolent course, and those
with no RET mutations have an intermediate risk [46].
5. MutationsActivateRET by Distinct
Mechanisms and Confer Somewhat Different
Oncogenic SignalingProperties
The functional basis for the diﬀerences in clinical expression
of distinct RET genotypes might be explained by the
recognition of mutation-speciﬁc mechanisms of activating
the RET proto-oncogene. Mutations in the extracellular
cysteine-rich region result in the replacement of a cysteine
residue by another amino acid, subsequently leading to loss
of an intramolecular disulﬁde bond. As a consequence, one
cysteine residue becomes available for the formation of an
intermolecular disulﬁde bond, which results in covalently
bound receptors that are constitutively active because of
ligand-independentreceptordimerization [29].Thesemuta-
tions commonly associate with MEN2A and FMTC. In con-
trast, the intracellular MEN2B-speciﬁc mutations and other
tyrosine kinase domain mutations aﬀect receptor activation
in a totally diﬀerent way. By altering the conformation of the
catalytic core of the tyrosine kinase domain they increase
catalytic activity and alter the spectrum of intracellular
substrates, resulting in remarkable changes of the signalling
properties of the receptor [29].
These observations highlight that distinct clinical pre-
sentations can arise from diﬀerences in the RET activation
mechanism and the corresponding output in terms of
oncogenicsignalling.However,notmuchisknownaboutthe
speciﬁc diﬀerences in signalling properties of the diﬀerent
RET mutants. Studies have shown that wild-type and
mutated RET display diﬀerences in the autophosphorylation
levels of docking sites, which are likely to lead to diﬀerential
activation of downstream cascades [47]. Support for this
paradigm comes from evidence that there are marked
diﬀerencesbetweenMEN2AandMEN2Bmutationsinterms
of their capacity for downstream PI3K/AKT activation.
This pathway seems to be more active in MEN2B than
in MEN2A [7], and this diﬀerence might be attributed to
an enhanced autophosphorylation of Y1062 caused by the
MEN2B mutation [48].
Another example concerns RET-induced activation of
STAT3. The MEN2A mutation Cys634Arg activates STAT3
independently of Janus tyrosine kinases (JAKs) [15]. How-
ever, the FMTC mutants, Tyr791Phe and Ser891Ala, seem to
do so through a diﬀerent route and need the involvement of
Src and JAKs in order to constitutively activate STAT3 [49].
Thus, on the basis of the above-mentioned evidence that
distinct signalling properties are displayed by RET mutants,
it is conceivable that diﬀerent sensitivity to the action of
tyrosine kinase inhibitors can occur due to the potentially
diﬀerent conformations of the receptor in each of the RET
mutants.
6.RET-TargetingTyrosineKinaseInhibitors
The small molecule tyrosine kinase inhibitors (TKIs) mecha-
nism of action is based on the principle that sterically block-
ing the ATP-binding pocket results in impaired phospho-
rylation activity, inhibits signal transduction, and prevents
activation of intracellular signalling pathways relevant to
tumor growth and angiogenesis.
The ﬁnding of various compounds (Table 1) capable of
inhibiting oncogenic RET (mutated or rearranged), such
as PP1 and PP2 [50], ZD6474 (Vandetanib) [51], RPI-
1[ 52], CEP-701, CEP-751 [66], Imatinib [67], Sunitinib
(SU5416, SU11248) [53], Geﬁtinib [55], Sorafenib (BAY 43-
9006)[57],Motesanib(AMG706)[59],Axitinib(AG013736)
[61] and XL 184, has brought further clinical relevance to
the classiﬁcation of the pharmacological sensitivity of RET
mutants, as metastatic MTC is the most common cause
of death in patients with MEN2 [68]. In addition, theseJournal of Thyroid Research 5
Table 1: Molecules used in preclinical and clinical trials as RET tyrosine kinase inhibitors.
Compound Trade name Structure Targets Clinical
trials
Refs
PP1 Zaleplon Pyrazolopyrimidine RET — [50]
PP2
ZD6474 Vandetanib Anilinoquinazoline RET; VEGFR; EGFR Phase II [51]
RPI-1 — Indolinone RET; MET — [52]
SU5416 Sunitinib Butanedioic acid VEGFR-2; PDGFR; c-KIT; RET; CSF-1R Phase II [53, 54]
SU11248
ZD1839 Geﬁtinib Anilinoquinazoline EGFR Phase II [55, 56]
BAY43-9006 Sorafenib Bis-aryl urea RAF-1; BRAF; VEGFR-2/-3; PDGFR-B; Flt-3; c-KIT; RET Phase II [57, 58]
AMG706 Motesanib diphosphate Diphosphate salt VEGFR; PDGFR; KIT; RET Phase II [59, 60]
AG-013736 Axitinib Benzamide RET; VEGFR; PDGFR; c-KIT Phase II [61]
XL184/XL880 VEGFR2; RET and MET Phase III [∗∗∗]
[∗∗∗]E d e re ta l .[ 62]. LoRusso et al. [63]. Ross et al. [64]. Salgia et al. [65].
compounds could ﬁnd application in radioactive iodine-
refractory PTC with RET/PTC rearrangements.
The pyrazolopyrimidines PP1 and PP2 and the 4-
anilinoquinazoline Vandetanib inhibit RET-rearrangement-
derived oncoproteins with a half maximal inhibitor concen-
tration (IC50) below 100nM. These molecules were shown
to inhibit RET enzymatic activity and phosphorylation
of downstream targets, such as ERK1/2. Vandetanib has
also been found to inhibit RET signalling in two human
PTC cell lines and to reduce tumorigenicity of RET/PTC-
transformed ﬁbroblasts injected into nude mice [50].
Vandetanib blocks in vivo phosphorylation and signalling
mediated by RET/PTC3 oncoprotein and of an epidermal
growth factor- (EGF-) activated EGF-receptor/RET chimeric
receptor. Finally, it blocks anchorage-independent growth of
RET/PTC3-transformed NIH3T3 ﬁbroblasts and the forma-
tion of tumors after injection of NIH-RET/PTC3 cells into
nude mice [51].
Sorafenib(BAY43-9006)wasdesignedoriginallyasaRAF
inhibitor [69]. Nonetheless, preclinical studies have shown
thatSorafenibcaninhibitthekinaseactivityandsignallingof
wild-typeandoncogenicRET.Sorafenibinhibitedoncogenic
RET kinase activity at an IC50 of 50nM or less in NIH3T3
cells. It arrested the growth of NIH3T3 and RAT1 ﬁbroblasts
transformed by oncogenic RET and of thyroid carcinoma
cells that harbour rearranged RET alleles. These inhibitory
eﬀects paralleled a decrease in RET phosphorylation [57].
Finally, PTC cells carrying the RET/PTC1 rearrangement
were found to be more sensitive to Sorafenib than PTC cells
carrying a BRAF mutation [70]. There is an ongoing phase
II clinical trial using Sorafenib in patients with advanced
thyroid cancer [58].
RPI-1 is a 2-indolinone derivative initially shown to
inhibit RET/PTC1 activity in an immunokinase assay with
an IC50 of 27–42μM. It selectively inhibited the anchorage-
independent growth of NIH3T3-transformed cells express-
ing the RET/PTC1 gene, and the transformed phenotype
of NIH3T3ptc1 cells was reverted to a normal ﬁbroblast-
like morphology. In these cells, the constitutive tyrosine
phosphorylation of RET/PTC1, of the transducing adaptor
protein Shc, and of a series of co-immunoprecipitated
peptides was substantially reduced [52]. Activation of JNK2
and AKT was abolished, thus supporting the drug inhibitory
eﬃcacy on downstream pathways. In addition, cell growth
inhibition was associated with a reduction in telomerase
activity by nearly 85% [71].
Sunitinib was initially described as a TKI targeting VEGF
and PDGFR receptors [72] and also found to inhibit c-
KIT [73]. It is now approved for the treatment of GIST
and renal cell carcinoma. In vitro kinase assays showed
that Sunitinib inhibited the phosphorylation by RET/PTC3
of a synthetic tyrosine kinase substrate peptide in a dose-
dependent manner. RET/PTC-mediated Y705 phosphoryla-
tion of STAT3 was inhibited by addition of Sunitinib, and
the inhibitory eﬀects of Sunitinib on tyrosine phosphory-
lation and transcriptional activation of STAT3 very closely
correlated with decreased autophosphorylation of RET/PTC.
Sunitinib caused a complete morphological reversion of
transformed NIH-RET/PTC3 cells and inhibited the growth
of TPC-1 cells that have an endogenous RET/PTC1 [53].
Treatment of two patients with progressive metastatic thy-
roid carcinoma (1 PTC and 1 FTC) demonstrated sustained
clinical responses to Sunitinib over a period of four years
[54].
Geﬁtinib was initially approved for nonsmall cell lung
cancer since it targets oncogenic EGFR. In vitro data
suggests that EGFR contributes to RET kinase activation,
signalling, and growth stimulation. Conditional activation
of RET/PTC oncoproteins in thyroid PCCL3 cells markedly
induced expression and phosphorylation of EGFR, which
was mediated in part through mitogen-activated protein
(MAP) kinase signalling. RET and EGFR were found to
co-immunoprecipitate. Ligand-induced activation of EGFR
resulted in phosphorylation of a kinase-dead RET, and
this eﬀect was entirely blocked by EGFR kinase inhibitor.
Geﬁtinib also inhibited cell growth induced by various
constitutively active mutants of RET in thyroid cancer cells
as well as in NIH3T3 cells [55]. These pieces of evidence have6 Journal of Thyroid Research
provided a biological basis for clinical evaluation of Geﬁtinib
in thyroid cancer. The results obtained in a phase II trial
showed no objective responses among the 25 thyroid cancer
patients treated with Geﬁtinib [56].
CEP-701 and CEP-751 are indolocarbazole derivatives
that also inhibit RET in MTC cells. Eﬀective inhibition
of RET phosphorylation in a dose-dependent manner is
achieved at concentrations <100nM. These compounds also
block the growth of MTC cells in culture. CEP-751 and
its prodrug, CEP-2563 inhibit tumor growth in MTC cell
xenografts [66]. These drugs also potentiate the eﬀects of
irinotecan treatment in TT cell culture and xenografts and
result in durable complete remission in 100% of the mice.
CEP-751 inhibited the induction of the DNA repair program
(marked by phospho-H2AX) as well as the checkpoint path-
way (marked by the activated Chk1) [74]. Since preclinical
modelshavedemonstratedthatbothCEP-751andCEP-2563
have antitumor activity in a variety of tumors, phase I trials
were undertaken [75].
Several other TKI molecules are being evaluated with
regard to their eﬃcacy in metastatic MTC treatment with
limited published data. Axitinib (AG-013736) [76]w a s
assessed in a phase II study with 60 MTC patients. Eighteen
cases (30%) presented partial responses, and 23 (38%) had
stable disease [61]. Motesanib (AMG706) [77] was evaluated
in diﬀerentiated thyroid cancer [59] and in a phase I study in
91patientswitheitherhereditary(16cases)orsporadicMTC
(75 cases), 2% of the patients showed partial response, and
81% had stable disease [60]. XL184/XL880 is a compound
that is rapidly going through the clinical evaluation process.
It is a TKI that targets VEGFR2, RET, and also MET
and whose eﬃcacy has been demonstrated for several solid
tumors, especially thyroid cancer [∗∗∗]. In patients with
hereditary and sporadic MTC very interesting response rates
were obtained with 9/17 patients (53%) showing partial
remission. Based on these ﬁndings, a phase III registration
trial of XL184 as a potential treatment for medullary thyroid
cancer (MTC) has been initiated.
7. The Inﬂuence of Genotype on the Sensitivity
toRET-TargetingTkIsandChallengesAhead
Although a number of patients with refractory MTC have
been undergoing treatment with several TKIs in the last few
years, it is not yet clear whether clinical response to these
drugs is actually inﬂuenced by the RET genotype of the
tumor cells. At this point, the only reliable source for this
type of information comes from in vitro studies. Indeed,
some compounds used against RET seem to conﬁrm the
paradigm that certain mutations can render RET resistant to
inhibition.ThiswasﬁrstillustratedbyPP1,PP2,andZD6474
(Vandetanib) which, despite being eﬃcient in inhibiting
phosphorylation of most of the MEN2-associated RET
mutants (at codons 768, 790, 883, 918, and 634 [50]), were
incapable of inhibiting MEN2-associated swap of Valine 804
for bulky hydrophobic Leucine or Methionine within the
RET kinase domain. Thus Valine 804 emerged as a structural
determinant amino acid mediating resistance to pyrazolopy-
rimidines and 4-anilinoquinazolines [78, 79]. This was also
found to be the case for the V804M/E805K tandem lesion,
detected in non-Met918/Ala883 MEN2B, which was shown
to also confer resistance to PP1, suggesting a mode of action
diﬀerent from the classical MEN2B mutations [33].
However, inhibition of RET phosphorylation and sig-
naling by mutation of the Val804 gatekeeper residue was
not impaired in cells subjected to Sorafenib treatment [80],
indicating thatthisdrugcouldbeapotential therapeutictool
for RET Val804 positive thyroid tumors [80].
The fact that using another compound can overcome a
mutation-speciﬁcprimaryresistancerendersfurthersupport
to the idea that sensitivity of RET mutants will, in the end,
result from mutation-dependent structural determinants of
theRETATP-bindingsite.However,tosupporttheparadigm
of an RET pharmacogenetics, much more needs to be
evaluated before we can conﬁrm that this concept is useful
for the clinical practice. To start, it would be imperative that
the mutation status of the tumors from patients included
in clinical trials is ascertained and correlated with clinical
response. Until now, none of the clinical studies have pub-
lishedthemutationstatusofthepatients. Ontheotherhand,
we must not forget that despite the in vitro data has proven
highly informative for genotype/phenotype correlations, it
cannot be taken directly to indicate diﬀerences in terms of
clinical response. In addition, many of these small molecule
inhibitors act upon several target RTKs, rendering it diﬃcult
to ascertain which of the eﬀects over diﬀerent RTKs actually
accounts for the observed clinical response.
We should also be aware that some of the eﬀects of
these compounds may go beyond interference with the ATP-
binding pocket and may aﬀect RET expression. For instance,
Sorafenib suppresses RET tyrosine kinase activity by direct
enzymatic inhibition and also by promoting RET lysosomal
degradation independent of proteasomal targeting [80].
At this point, given that a number of molecules are
starting to become available, it would be worth to compare
these drugs against each other in their eﬃcacy to inhibit the
activity of the most frequent RET genotypes. This may come
asameanstodeﬁneandstratifydrugsforuseasﬁrst-lineand
second-line treatments on the basis of the RET genotype.
As we highlighted before, speciﬁc RET mutations may
lead stronger induction of speciﬁc intracellular signalling
targets, many of which have their own dedicated inhibitors
under development. In this respect, the information about
the speciﬁcities in oncogenic signalling of diﬀerent geno-
types might be valuable to design combinatorial therapies
employing mutation-speciﬁc combinations of inhibitors for
treatment.
Atpresent,theclinical useoftyrosine kinase inhibitors in
patients with thyroid cancer still does not rely in the genetic
background of each tumor [58, 61, 81]. Nonetheless, results
from clinical trials suggest that these compounds have a
more cytostatic than cytolytic eﬀect, and thus are just adding
another step of selective pressure to the progressing tumor
(which buys time), but eventually secondary resistance can
develop. In models such as ABL/CML (imatinib), EGFR/lung
cancer (Geﬁtinib), or KIT/GIST (imatinib), prolongedJournal of Thyroid Research 7
therapy with TKIs leads to the acquisition of resistance
mutations in the receptors targeted by these drugs, rendering
them insensitive to therapy. Although no secondary RET
mutations have been described thus far, the experience with
patients undergoing clinical trials taught that some patients
suddenly fail to respond while on treatment. Most probably,
the same underlying resistance mechanisms are at play. This
implies that, in order to translate the use of these inhibitors
into increased long-term survival, we may need to perform
molecular followup of the progressing lesions, in order to
predict resistance and eventually change from one inhibitor
to another.
Finally, to reduce the biology of MTC to RET activation
and signaling boosting is almost certainly a simplistic view.
RET mutations do not only determine MTC development
(even in hMTC). Likely these tumours also carry mutations
in other genes, and possibly one should also know these
to think about combinatory therapies. Indeed, data is
accumulating regarding alternative pathways that contribute
to MTC development from precursor C-cell hyperplasia.
This is the case of the WNT pathway activation by RET-
mediated tyrosine phosphorylation of β-Catenin [11]a n d
the synergistic eﬀects of p18 and p27, two members of the
RB pathway [82, 83]. This may provide additional targets
for combination of RET inhibitors with other compounds
targeting these pathways. Also relevant to this is the recent
recognition of mechanisms of cross-talk between diﬀerent
RTKs. For instance, EGFR may cooperate with RET in acti-
vating intracellular signaling pathways [55]. This provides
biological basis for combining diﬀerent RTK inhibitors.
The challenge for the years to come is to use the pools of
knowledge generated in RET signaling pathways and MTC
progression steps to rationalize combinatory therapies, tar-
geting diﬀerent molecules and diﬀerent signaling pathways
that are relevant in MTC.
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